ScreenCell® technology is based on a patented and unique microfiltration principle, enabling the isolation of circulating tumor cells (CTCs) from a simple blood sample.
ScreenCell® technology is a versatile liquid biopsy platform designed for the non-invasive detection of circulating tumor cells (CTCs) from a simple blood draw in patients with solid tumors.
It is available in seven single-use kits, each specifically designed for distinct applications in circulating tumor cell detection.
Explore the full range of ScreenCell® CTC isolation kits, each specifically designed to meet the diverse needs of liquid biopsy applications.
FCD
Blood sample
< 3 days
or
Cells fixed detached
from the isolation support for analysis in suspension or on slide
FCD-SP
Blood sample
< 4 hours
or
Cells fixed detached
from the isolation support for analysis in suspension or on slide
Blood sample
< 4 hours
Living cells detached
from the isolation support for suspension analysis
Blood sample
< 4 hours
Living cells detached
from the isolation support for suspension analysis
MGG Staining
Immunofluorescence
Immunocytochemistry
FISH
2D Cell Culture
3D Cell Culture
DNA extraction
RNA extraction
Discover a multitude of downstream analyses achievable with our circulating tumor cell test and choose the one you need across our three areas of expertise: cytology, molecular biology and cell culture.
ScreenCell® technology stands out from other methods due to its remarkable ease of use.
It provides users with the ability to efficiently and quickly detect circulating tumor cells (CTCs), without any machine-related constraints, in just three simple steps: dilution, filtration, and ejection.
Fill in the fields below and we’ll take care of the rest.
Follow ScreenCell on LinkedIn
